GR3025950T3 - 2-substituted morpholine and thiomorpholine derivatives as gaba- b? antagonists - Google Patents

2-substituted morpholine and thiomorpholine derivatives as gaba- b? antagonists

Info

Publication number
GR3025950T3
GR3025950T3 GR980400120T GR980400120T GR3025950T3 GR 3025950 T3 GR3025950 T3 GR 3025950T3 GR 980400120 T GR980400120 T GR 980400120T GR 980400120 T GR980400120 T GR 980400120T GR 3025950 T3 GR3025950 T3 GR 3025950T3
Authority
GR
Greece
Prior art keywords
pct
formula
gaba
antagonists
sec
Prior art date
Application number
GR980400120T
Other languages
Greek (el)
English (en)
Inventor
Shen-Chun Kuo
David J Blythin
William Kreutner
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of GR3025950T3 publication Critical patent/GR3025950T3/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/121,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • C07F9/65335Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR980400120T 1993-03-26 1998-01-20 2-substituted morpholine and thiomorpholine derivatives as gaba- b? antagonists GR3025950T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3858493A 1993-03-26 1993-03-26
PCT/US1994/002803 WO1994022843A1 (en) 1993-03-26 1994-03-23 2-substituted morpholine and thiomorpholine derivatives as gaba-b antagonists

Publications (1)

Publication Number Publication Date
GR3025950T3 true GR3025950T3 (en) 1998-04-30

Family

ID=21900746

Family Applications (1)

Application Number Title Priority Date Filing Date
GR980400120T GR3025950T3 (en) 1993-03-26 1998-01-20 2-substituted morpholine and thiomorpholine derivatives as gaba- b? antagonists

Country Status (14)

Country Link
US (1) US5929236A (en, 2012)
EP (1) EP0690850B1 (en, 2012)
JP (1) JP2778832B2 (en, 2012)
AT (1) ATE160143T1 (en, 2012)
AU (1) AU6408894A (en, 2012)
CA (1) CA2158952C (en, 2012)
DE (1) DE69406779T2 (en, 2012)
DK (1) DK0690850T3 (en, 2012)
ES (1) ES2109683T3 (en, 2012)
GR (1) GR3025950T3 (en, 2012)
IL (1) IL109111A (en, 2012)
TW (1) TW280817B (en, 2012)
WO (1) WO1994022843A1 (en, 2012)
ZA (1) ZA942090B (en, 2012)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853626A1 (en) * 1995-09-07 1998-07-22 Novartis AG Substituted phosphinic compounds and their use as pharmaceuticals
AU5859598A (en) * 1996-12-24 1998-07-17 Novartis Ag (thio)morpholine-substituted carboxylic and phosphinic acids
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889857A (en) * 1987-10-12 1989-12-26 Yoshitomi Pharmaceutical Industries, Ltd. Quinolonecarboxylic acid compounds and pharmaceutical use thereof
NZ233503A (en) * 1989-05-15 1991-06-25 Janssen Pharmaceutica Nv Substituted (thio)morpholinyl and piperazinyl alkylphenol ethers
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法

Also Published As

Publication number Publication date
TW280817B (en, 2012) 1996-07-11
AU6408894A (en) 1994-10-24
DE69406779D1 (en) 1997-12-18
ES2109683T3 (es) 1998-01-16
EP0690850A1 (en) 1996-01-10
IL109111A0 (en) 1994-06-24
CA2158952A1 (en) 1994-10-13
ATE160143T1 (de) 1997-11-15
ZA942090B (en) 1994-09-26
CA2158952C (en) 1999-05-18
WO1994022843A1 (en) 1994-10-13
JPH08503229A (ja) 1996-04-09
JP2778832B2 (ja) 1998-07-23
IL109111A (en) 1999-07-14
US5929236A (en) 1999-07-27
DK0690850T3 (da) 1998-02-09
EP0690850B1 (en) 1997-11-12
DE69406779T2 (de) 1998-03-12

Similar Documents

Publication Publication Date Title
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
MY140525A (en) Pharmaceutical uses for alpha2delta ligands
CA2241904A1 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
CA2252515A1 (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
GR3025950T3 (en) 2-substituted morpholine and thiomorpholine derivatives as gaba- b? antagonists
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
RU94044454A (ru) Ингибитор аутоимунных заболеваний
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
TR199701497T1 (xx) Beyin �demini �nleyen terkip.
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
ES8601915A1 (es) Un procedimiento para preparar derivados de piridazinona
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
TW244336B (en, 2012)
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
ES2138017T3 (es) Uso de n-(piridinil)-1h-indol-1-aminas para la preparacion de un medicamento para el tratamiento de trastornos obsesivo-compulsivos.
BR9809313A (pt) Compostos, promedicamento, medicamento, processo para a sua preparação e utilização dos mesmos
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
UA66751C2 (en) Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment
ES552193A0 (es) Un procedimiento para la preparacion de nuevos peptidos.
ES2065855A1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.